Medtech giant, Boston Scientific, has swung a European CE marking for its Vercise Neural Navigator 5 Software, designed to be used as part of the company’s Deep Brain Stimulation (DBS) system for the treatment of Parkinson’s disease.
Used alongside the company’s DBS device, the Vercise Neural Navigator 5 Software was created to provide clinicians with actionable data, based on readings taken from the patient, aimed at helping them to better program a patient's DBS device to their specific needs.
It follows after the company’s DBS device received its initial clearance from the European Commission in 2020. Research by GlobalData estimates that in 2023 the market for neuromodulation devices stood at around $1.2bn worldwide, with that figure estimated to grow to $1.9bn by the end of 2030.
At the same time, additional research from GlobalData found that the majority of early-stage patients in Parkinson’s disease patients receive drug therapy in 74%-88% of cases, rising to 82%-95% in advanced-stage patients. Only approximately 5%-10% of patients are referred for a deep brain stimulation (DBS) procedure.
Vincent Sourdaine, vice president of neuromodulation for Boston Scientific, said: “Our aim is to develop tools that make a meaningful difference to physicians and to people living with neurological conditions alike.
“This software enables more efficiency with DBS therapy to simplify what can otherwise be a time-consuming procedure, freeing up capacity for hospitals and clinicians for more value-added tasks and to provide optimal care for patients.”
Boston Scientific says that the new software comes with an enhanced user interface that displays patient data in a simplified format giving clinicians access to advanced settings for increased therapy delivery.
Francesca Morgante, professor of Neurology at St. George’s University in London, said: “We are now using image-guided programming tools to optimally define the site of stimulation while we clinically assess the patient. This advancement in the technology has substantially cut down our programming time and allowed us to improve the symptoms of our patients in a significantly shorter time.”
Elsewhere in the field of neuromodulation, the US-based company Neuromod USA has signed a deal with the US Government to ensure its tinnitus device, Lenire, is an option for veterans through the Department of Veterans Affairs (VA).
